Related Experiment Video

Updated: Nov 5, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Heart Failure with Supra-normal Left Ventricular Ejection Fraction - State of the Art

Ziyin Huang1, Yufeng Jiang1, Yafeng Zhou1,2

  • 1First Affiliated Hospital of Soochow University, Jiangsu Province - China.

Arquivos Brasileiros De Cardiologia
|May 19, 2021
PubMed

Insights

Heart failure with supra-normal ejection fraction (HFsnEF) is a new phenotype where patients face higher mortality than those with preserved ejection fraction (HFpEF). Understanding HFsnEF is crucial for better patient treatment and further research.

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • A novel heart failure (HF) phenotype, heart failure with supra-normal left ventricular ejection fraction (HFsnEF) (LVEF ≥ 65%), was identified in 2019.
  • Research into HFsnEF is essential due to observed higher all-cause mortality compared to HF with preserved ejection fraction (HFpEF).

Purpose of the Study:

  • To describe the current understanding and situation of the HFsnEF phenotype.
  • To discuss future research directions for HFsnEF based on preliminary findings.
  • To highlight the importance of differentiating HFsnEF from other HF phenotypes for effective clinical management.

Main Methods:

  • Analysis of mortality data in relation to left ventricular ejection fraction (LVEF) in heart failure patients.
  • Review and synthesis of existing literature on HFsnEF.
  • Presentation of preliminary results from the authors' research group.

Main Results:

  • A U-shaped relationship was observed between LVEF and mortality in heart failure patients.
  • Patients with HFsnEF exhibited higher all-cause mortality compared to patients with HFpEF.
  • Preliminary data suggests unique characteristics of the HFsnEF population.

Conclusions:

  • HFsnEF represents a distinct HF phenotype with significant mortality implications.
  • A deeper understanding of HFsnEF's unique characteristics is necessary for improved therapeutic strategies.
  • Further research is warranted to elucidate the pathophysiology and optimize treatment for HFsnEF patients.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

14.7K

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
105
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
64
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
144
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
114
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69